Stay updated with breaking news from Patrick Forde. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Constable Patrick Forde said he was on mobile patrol along the Adams section of the ABC Highway on March 21, 2019, when he received information about a suspect in a murder case being transported in a red Mazda bearing the licence plate MC 92. Forde was one of nine witnesses giving testimony yesterday in the No. 3 Supreme Court in the trial of Hakeem Stuart, who has pleaded not guilty …
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.
Canva; Everyday Health The annual meeting of the American Association for Cancer Research (AACR) is one of the largest cancer research meetings of its kind, bringing together a range of researchers, from those who spend their time in the lab to those who focus on patients in the clinic. The meeting atmosphere is electric — even when it’s virtual. Here are five key studies that stood out during the first week of the virtual AACR meeting, held April 10–15, 2021. Lymphoma Progression Cut in Half When Rituxan Is Paired With Aliqopa What’s new Patients with relapsed indolent non-Hodgkin ...
Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients Combination increases complete response rate to 24% compared to chemotherapy alone Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting. Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with early-stage NSCLC before surgery. The primary endpoints of the study were pathological complete res...